Ms. Julie A Javernick, CNM Advanced Practice Midwife Medicare: Medicare Enrolled Practice Location: 7950 Kipling St, Suite 201, Arvada, CO 80005 Phone: 303-424-6466 Fax: 303-420-8944 |
Kathryn Ann Smith, CNM Advanced Practice Midwife Medicare: Medicare Enrolled Practice Location: 7402 W 67th Pl, Arvada, CO 80003 Phone: 774-613-1413 |
Andrea Talarico, CNM Advanced Practice Midwife Medicare: Medicare Enrolled Practice Location: 7950 Kipling Parkway Ste. 201, Arvada, CO 80005 Phone: 303-424-6466 |
Norine M Taylor, CNM Advanced Practice Midwife Medicare: Medicare Enrolled Practice Location: 7950 Kipling St, Suite 201, Arvada, CO 80005 Phone: 303-424-6466 Fax: 303-420-8944 |
News Archive
To help manage the growing incidence of cancer, China's Health Department of the People's Liberation Army has ordered a comprehensive range of clinical solutions from Elekta. Fourteen hospitals around the country will receive in total 15 linear accelerators (linacs).
A new ADD/ADHD study found that a multi-modal hemispheric based program significantly improved the participant's educational outcomes. The study, "The Effect of Hemispheric Specific Remediation Strategies on the Academic Performance Outcome of Children With ADD/ADHD," was conducted by a research team including, Gerry Leisman, Robert Melillo, Sharon Thum, Mark Ransom, Michael Orlando, Christopher Tice, and Frederick Carrick. The study appears in the current issue of the International Journal of Adolescent Medicine and Health.
A study by investigators at Case Western Reserve University School of Medicine published in this week's issue of JAMA found that public hospital comparison data reported by the U.S. Department of Health and Human Services does not accurately correlate with a patient's risk for surgical postoperative infection.
TxCell SA, a biotechnology company developing innovative, personalized cell-based immunotherapies using antigen specific regulatory T-cells for severe chronic inflammatory and autoimmune diseases, announces today that the United States Food and Drug Administration has granted Fast Track Designation to TxCell's lead product Ovasave for the treatment of moderate to severe Crohn's disease.
As its name suggests, inflammatory bowel disease, which afflicts more than 1.6 million Americans, involves chronic inflammation of all or some of the digestive tract. An autoimmune disease known to have a strong genetic component, its symptoms are abdominal cramps, bloody diarrhea, and fever and, sometimes, weight loss. IBD, which is a group of inflammatory conditions, includes Crohn's disease and ulcerative colitis.
› Verified 2 days ago